Health Canada Approves Illuccix® for Prostate Cancer Imaging

Article: https://telixpharma.com/news-views/health-canada-approves-illuccix-for-prostate-cancer-imaging/

Health Canada Approves Illuccix® for Prostate Cancer Imaging

Telix announces that Health Canada has approved Illuccix® [kit for the preparation of gallium (68Ga) gozetotide injection] for use in staging and re-staging intermediate and high-risk prostate cancer and localizing tumour tissue in recurrent prostate cancer.

Illuccix™ [kit for the preparation of gallium (68Ga) gozetotide injection], after radiolabeling with gallium (68Ga), is indicated for use with the positron emission tomography (PET) of prostate specific membrane antigen (PSMA) positive lesions in men with prostate cancer:
• with suspected metastasis who are suitable for initial definitive therapy
• with suspected recurrence with elevated serum prostate specific antigen (PSA) level.

“PSMA PET” (or the imaging of Prostate-Specific Membrane Antigen (PSMA) via a positron emission tomography (PET) scan) is a diagnostic tool demonstrated to detect advanced prostate cancer.

Illuccix is the first PSMA PET imaging agent to be granted regulatory approval in Canada. Health Canada is the third regulatory body worldwide to approve Illuccix, which is commercially available in Australia and the United States.

Dr. Norman Laurin, current president of the Quebec Association of Nuclear Medicine Specialists and past president of the Canadian Association of Nuclear Medicine said, “On average, 67 men in Canada are diagnosed with prostate cancer each day. Early detection, along with better understanding of the spread and stage of the disease can lead to more informed disease management decisions. Tools such as Illuccix are valuable as we look for better ways to detect prostate cancer in men.”

Kevin Richardson, CEO Telix Americas said, “PSMA PET imaging has been one of the most important developments in prostate cancer detection in recent years and we are very pleased that we can now bring this important diagnostic imaging agent to physicians and their patients across Canada.”

Illuccix will be made available in Canada to physicians and eligible patients through Telix’s partner, Isologic Innovative Radiopharmaceuticals (ISOLOGIC), whose distribution network services 265 hospitals and clinics nationwide.

About Prostate Cancer in Canada

According to the Canadian Cancer Society, prostate cancer is the most common cancer and the third-leading cause of death from cancer among Canadian men. More than 24,000 men in Canada are estimated to be diagnosed with prostate cancer this year, and 4,600 will die from the condition. Reliable and flexible diagnostic tools are essential for medical teams in narrowing the gap between understanding the spread of disease and the development of individualized treatment plans.


According to the Canadian Cancer Society, prostate cancer is the most common cancer and the third-leading cause of death from cancer among Canadian men. More than 24,000 men in Canada are estimated to be diagnosed with prostate cancer this year, and 4,600 will die from the condition. Reliable and flexible diagnostic tools are essential for medical teams in narrowing the gap between understanding the spread of disease and the development of individualized treatment plans

To return to the Initio homepage please click here.

Forms

Upon receiving your requisition INITIO staff will contact you via phone to gather your detailed medical history. They will fill out the appropriate intake package on your behalf. Upon your arrival at the clinic, you will be given the opportunity to review and make any necessary edits to your intake package before signing.

Alternatively, you may print the intake package at home, fill out the forms with your medical history and send it to us either through fax: (604) 678–9279 or via e-mail: info@initiomedical.ca. If you are sending us an intake package please ensure that your doctor has sent us a requisition.

As per the INITIO Medical Group Inc. cancellation policy, at the time of booking, we ask each patient to provide us with their credit card details. This information is used in the event that the patient cancels their appointment, or fails to attend their scheduled appointment.

Please note that no charges are made to the credit card on file, except in the event of an appointment cancellation or a failure to attend a scheduled appointment. All charges for the scan are made in person upon completion of the appointment, at which point the credit card authorization form will be shredded.

  • CT Scans
    Booking Fee: $50
    Cancellation Fee: $100
  • PET Amyloid Scans
    Booking Fee: $750
    Cancellation Fee: $2000
  • PET FDG Scans
    Booking Fee: $500
    Cancellation Fee: $1000
  • PET PSMA Scans
    Booking Fee: $500
    Cancellation Fee: $1000